2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2414

Knowledge and Adherence to Current Immunization Recommendations in Patients with Rheumatoid Arthritis in Mexico
Abstract Number: 2415

Immunogenicity and Persistence of a Prime-Boost Re-Vaccination Strategy for Pneumococcal Vaccines (13-Valent Pneumococcal Conjugate Vaccine + 23-Valent Pneumococcal Polysaccharide Vaccine) in Patients with Rheumatoid Arthritis: A Pilot Study
Abstract Number: 2416

Histopathological Change Caused By Biological Treatment in Rheumatoid Arthritis Synovial Tissue
Abstract Number: 2417

Occult Coronary Plaque Presence and Burden Predict Cardiovascular Events in Patients with Rheumatoid Arthritis
Abstract Number: 2418

Tissue-Engineered Human Skeletal Muscle Model of Rheumatoid Arthritis
Abstract Number: 2419

Immunomodulatory Effects of Bone-Marrow Mesenchymal Stem Cells in Rheumatoid Arthitis: Influence of Disease Activity
Abstract Number: 2420

Mass Cytometry Analysis of CD4+ T Cells in Patients with Rheumatoid Arthritis
Abstract Number: 2421

Aberrant Expression of CaMK4 in CD4 Positive T Cells Predicts Poor Response to Treatment in Patients with Active Rheumatoid Arthritis
Abstract Number: 2422

Rheumatoid Arthritis (RA) Synovial Fluid Treg Cells Secrete IL-17 and at the Same Time Are Potent Suppressors of Tresp Cell Proliferation, TNF-α and Interferon γ Production
Abstract Number: 2423

Patients with Active Rheumatoid Arthritis but Normal Levels of Acute Phase Proteins Have Altered Regulatory T Cell Function and Rapidly Progress to Biological Therapies
Abstract Number: 2424

CD8-Positive Lymphocytes in Biopsy Specimens Predict Spontaneous Regression of Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis Treated with Methotrexate
Abstract Number: 2425

Decline in CD8+IFNγ+ Subset but Rise in CD8+IL17+ on Methotrexate Treatment in Rheumatoid Arthritis
Abstract Number: 2426

Altered Frequencies of Circulating Follicullar T Helper Cell Counterparts and Their Subsets but Not of Peripheral Helper T Cells, Are Associated with Increased Circulating Plasmablasts in Seropositive Early RA Patients
Abstract Number: 2427

Exosomes Derived from T Lymphocytes Enhance Expression of CXCL10 Induced By IFN-γin Rheumatoid Arthritis Synovial Fibroblasts Via Pattern Recognition Receptor, RIG-I
Abstract Number: 2428

Epstein-Barr Virus Infection and Epstein-Barr Virus　Nuclear Antigen 1 Variants in the Synovial Tissue of Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].